medigraphic.com

2023, Number 3

<< Back Next >>

Rev Fac Med UNAM 2023; 66 (3)

Poppy, beautiful poppy: opiates and opioids, utility and risks

Herrera SA, Ostos VA, Ruiz CAE; Méndez DM Cortés MJ, Chavira ESC, Prospéro GOE

Language: Spanish
References: 40
Page: 8-26
PDF size: 773.31 Kb.


ABSTRACT

Opium and its derivatives, and recently the opioids have accompanied the humankind since the ancient civilizations to the present day. Its analgesic, hypnotic and pleasant effects did not go unnoticed by ancient people, which considered most of these effects of medical utility and noticed that they had remarkable mood benefits. Currently, there are no other kind of drugs that can palliate intense pain as efficiently as these powerful analgesics. However, the medical and recreational use of opiates and opioids may carry health risks such as tolerance, hyperalgesia, and addiction. Nowadays, in addition to being indisputably the most powerful medical treatment to alleviate the suffering caused by pain, it has also become a public health problem due to the high number of people with opioid use disorder that have facilitated deaths caused by opioids overdose. In this review we will discuss the medical benefits of opiates and opioids, as much as the unwanted effects they produce.


REFERENCES

  1. Congreso de los Estados Unidos Mexicanos. Ley Generalde Salud. México: Diario Oficial de la Federación. 16 deMayo de 2022; 2022. p. 342.

  2. International Association for the Study of Pain. IASP AnnouncesRevised Definition of Pain Washington, D.C.USA: IASP; 2023. Disponible en: https://www.iasp-pain.org/publications/iasp-news/iasp-announces-revised-definition-of-pain/.

  3. Solomon RL, Corbit JD. An opponent-process theory ofmotivation. I. Temporal dynamics of affect. Psychol Rev.1974;81(2):119-45.

  4. Miller AH, Maletic V, Raison CL. Inflammation and itsdiscontents: the role of cytokines in the pathophysiologyof major depression. Biol Psychiatry. 2009;65(9):732-41.

  5. Sun L, Peng C, Joosten E, Cheung CW, Tan F, Jiang W,et al. Spinal Cord Stimulation and Treatment of Peripheralor Central Neuropathic Pain: Mechanisms and ClinicalApplication. Neural Plast. 2021;2021:5607898.

  6. Cox BM. A Concise Review of Concepts in Opioid Pharmacologyup to the Discovery of Endogenous Opioids. MolPharmacol. 2020;98(4):392-400.

  7. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, MorganBA, Morris HR. Identification of two related pentapeptidesfrom the brain with potent opiate agonist activity.Nature. 1975;258(5536):577-80.

  8. Lazarus LH, Ling N, Guillemin R. beta-Lipotropin as aprohormone for the morphinomimetic peptides endorphinsand enkephalins. Proc Natl Acad Sci USA. 1976;73(6):2156-9.

  9. Cox BM, Goldstein A, Hi CH. Opioid activity of a peptide,beta-lipotropin-(61-91), derived from beta-lipotropin. ProcNatl Acad Sci USA. 1976;73(6):1821-3.

  10. Li CH. Lipotropin, a New Active Peptide from PituitaryGlands. Nature. 1964;201:924.

  11. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M,Hood L. Dynorphin-(1-13), an extraordinarily potent opioidpeptide. Proc Natl Acad Sci USA. 1979;76(12):6666-70.

  12. Todorov P, Georgieva S, Tchekalarova J. Recent Synthesis,Characterization, and Pharmacological Evaluation ofMultifunctional Hemorphins Containing Non-NaturalAmino Acids with Potential Biological Importance. Pharmaceuticals(Basel). 2022;15(11).

  13. Takagi H, Shiomi H, Ueda H, Amano H. A novel analgesicdipeptide from bovine brain is a possible Met-enkephalinreleaser. Nature. 1979;282(5737):410-2.

  14. Woodford KB. Casomorphins and Gliadorphins Have DiverseSystemic Effects Spanning Gut, Brain and InternalOrgans. Int J Environ Res Public Health. 2021;18(15).

  15. Brownstein MJ. A brief history of opiates, opioid peptides,and opioid receptors. Proc Natl Acad Sci USA. 1993;90(12):5391-3.

  16. Aragón-Poce F, Martínez-Fernández E, Márquez-EspinósC, Pérez A, Mora R, Torres LM. History of opium. InternationalCongress Series. 2002;1242:19-21.

  17. Escohotado A. Historia Elemental de las Drogas. La Emboscadura;2022. 190 p.

  18. United Nations Office on Drugs and Crime. World DrugReport 2022 Vienna, Austria, 2022. Disponible en: https://www.unodc.org/unodc/data-and-analysis/world-drug-report-2022.html.

  19. Schiff PL (editor). Opium and Its Alkaloids; 2004.

  20. Lockermann G. Friedrich Wilhelm Serturner, the discovererof morphine. Journal of chemical education. 1951;28(5):277.

  21. Schmitz R. Friedrich Wilhelm Serturner and the discoveryof morphine. Pharm Hist. 1985;27(2):61-74.

  22. Brook K, Bennett J, Desai SP. The Chemical History ofMorphine: An 8000-year Journey, from Resin to de-novoSynthesis. J Anesth Hist. 2017;3(2):50-5.

  23. Wood A. New Method of Treating Neuralgia by the DirectApplication of Opiates to the Painful Points. Edinb MedSurg J. 1855;82(203):265-81.

  24. Cichon J, Liu R, Le HV. Therapeutic Potential of SalvinorinA and Its Analogues in Various Neurological Disorders.Transl Perioper Pain Med. 2022;9(2):452-7.

  25. McCurdy CR, Sufka KJ, Smith GH, Warnick JE, NietoMJ. Antinociceptive profile of salvinorin A, a structurallyunique kappa opioid receptor agonist. Pharmacol BiochemBehav. 2006;83(1):109-13.

  26. Díaz JL. Salvia divinorum: enigma psicofarmacológico yresquicio mente-cuerpo. Salud mental. 2014;37(3):183-93.

  27. Vazquez-Leon P, Arenas-Martinez U, Cordova-MaquedaD, Fregoso-Aguilar T, Juan ER, Miranda-Paez A. Salviadivinorum increases alcohol intake and tonic immobilitywhilst decreasing food intake in Wistar rats. Acta NeurobiolExp (Wars). 2021;81(1):34-42.

  28. Todorovic SM. Opioid-induced hyperalgesia: Are thalamicT-type calcium channels treatment targets? J Clin Invest.2022;132(24).

  29. Lee M, Silverman SM, Hansen H, Patel VB, ManchikantiL. A comprehensive review of opioid-induced hyperalgesia.Pain Physician. 2011;14(2):145-61.

  30. Jin Y, Mao Y, Chen D, Tai Y, Hu R, Yang CL, et al. Thalamocorticalcircuits drive remifentanil-induced postoperativehyperalgesia. J Clin Invest. 2022;132(24).

  31. Koponen ME, Forget P. Pharmacological Interventionsfor Opioid-Induced Hyperalgesia: A Scoping Review ofPreclinical Trials. J Clin Med. 2022;11(23).

  32. Gamble MC, Williams BR, Singh N, Posa L, Freyberg Z,Logan RW, et al. Mu-opioid receptor and receptor tyrosinekinase crosstalk: Implications in mechanisms of opioid tolerance,reduced analgesia to neuropathic pain, dependence,and reward. Front Syst Neurosci. 2022;16:1059089.

  33. Koob GF. Drug Addiction: Hyperkatifeia/Negative Reinforcementas a Framework for Medications Development.Pharmacol Rev. 2021;73(1):163-201.

  34. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology.2010;35(1):217-38.

  35. Koob GF. The role of CRF and CRF-related peptides inthe dark side of addiction. Brain Res. 2010;1314:3-14.

  36. Baumgartner HM, Schulkin J, Berridge KC. ActivatingCorticotropin-Releasing Factor Systems in the NucleusAccumbens, Amygdala, and Bed Nucleus of Stria Terminalis:Incentive Motivation or Aversive Motivation? BiolPsychiatry. 2021;89(12):1162-75.

  37. Drug Enforcement Administration. Fentanyl Trade Names:Actiq, Fentora, Duragesic E.U.A: DEA, Diversion ControlDivition, Drug & Chemical Evaluation Selection; 2023.Disponible en: https://www.deadiversion.usdoj.gov/drug_chem_info/fentanyl.pdf.

  38. National Instutute on Drug Abuse. Drug overdose deathRates U.S.A.: National Institutes of Health; 2023 [citado:14 de diciembre de 2022]. Disponible en: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates.

  39. Defalque RJ, Wright AJ. The early history of methadone.Myths and facts. Bull Anesth Hist. 2007;25(3):13-6.

  40. Campbell ND, Lovell AM. The history of the developmentof buprenorphine as an addiction therapeutic. Ann N YAcad Sci. 2012;1248:124-39.




2020     |     www.medigraphic.com